Once-Monthly Exenatide Injection Developed for Treating Diabetes in Cats
A hydrogel microsphere delivery system enables once-monthly exenatide injections for diabetic cats, using a self-cleaving linker to slowly release the GLP-1 drug over weeks.
Quick Facts
What This Study Found
A hydrogel microsphere delivery system with a self-cleaving β-eliminative linker enables sustained release of exenatide from a single subcutaneous injection, providing once-monthly dosing for feline diabetes treatment.
Key Numbers
Bioavailability: 93% ([Gln28]exenatide) vs 52% (exenatide); depot half-life ~40 days vs ~40 min free peptide; dose 10 mcg/kg
How They Did This
Developed hydrogel microspheres covalently attached to exenatide via β-eliminative linkers. Tested pharmacokinetics and glycemic effects after subcutaneous injection in diabetic cats.
Why This Research Matters
Feline diabetes is common and typically requires twice-daily insulin injections. A once-monthly GLP-1 treatment could dramatically improve compliance and quality of life for both cats and their owners.
The Bigger Picture
This delivery technology has broader implications — the same microsphere-linker platform could extend the duration of other peptide drugs in veterinary and potentially human medicine.
What This Study Doesn't Tell Us
Small sample size. Preliminary pharmacokinetic and efficacy data. Long-term safety of repeated monthly injections not established. Cost comparison with insulin therapy not addressed.
Questions This Raises
- ?How does the glycemic control from monthly exenatide compare to twice-daily insulin in cats?
- ?Could this delivery platform be applied to human GLP-1 drugs?
- ?What are the injection site reactions from hydrogel microspheres over multiple months?
Trust & Context
- Key Stat:
- Once monthly vs daily Hydrogel microsphere technology extends exenatide from daily to monthly injections for diabetic cats
- Evidence Grade:
- Preliminary — proof of concept with small sample; larger studies needed for clinical validation in veterinary practice.
- Study Age:
- Published in 2020; long-acting GLP-1 formulations for veterinary use continue development.
- Original Title:
- A once-monthly GLP-1 receptor agonist for treatment of diabetic cats.
- Published In:
- Domestic animal endocrinology, 70, 106373 (2020)
- Authors:
- Schneider, E L, Reid, R, Parkes, D G, Lutz, T A, Ashley, G W, Santi, D V
- Database ID:
- RPEP-05115
Evidence Hierarchy
Frequently Asked Questions
Why is a once-monthly injection important for cat diabetes?
Most diabetic cats need twice-daily insulin injections, which is stressful for both cats and owners. A once-monthly treatment at the veterinary clinic eliminates daily injections, improving compliance and quality of life.
How does the slow-release technology work?
Exenatide is attached to tiny hydrogel beads via a chemical bond that slowly breaks down under the skin. As the bond cleaves, the drug is gradually released over weeks, maintaining therapeutic levels from a single injection.
Read More on RethinkPeptides
Cite This Study
https://rethinkpeptides.com/research/RPEP-05115APA
Schneider, E L; Reid, R; Parkes, D G; Lutz, T A; Ashley, G W; Santi, D V. (2020). A once-monthly GLP-1 receptor agonist for treatment of diabetic cats.. Domestic animal endocrinology, 70, 106373. https://doi.org/10.1016/j.domaniend.2019.07.001
MLA
Schneider, E L, et al. "A once-monthly GLP-1 receptor agonist for treatment of diabetic cats.." Domestic animal endocrinology, 2020. https://doi.org/10.1016/j.domaniend.2019.07.001
RethinkPeptides
RethinkPeptides Research Database. "A once-monthly GLP-1 receptor agonist for treatment of diabe..." RPEP-05115. Retrieved from https://rethinkpeptides.com/research/schneider-2020-a-oncemonthly-glp1-receptor
Access the Original Study
Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.
This study breakdown was produced by the RethinkPeptides research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.